Compare · MYO vs STE
MYO vs STE
Side-by-side comparison of Myomo Inc. (MYO) and STERIS plc (Ireland) (STE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYO and STE operate in Industrial Specialties (Health Care), so they compete in similar markets.
- STE is the larger of the two at $23.05B, about 393.3x MYO ($58.6M).
- Over the past year, MYO is up 31.4% and STE is down 4.9% - MYO leads by 36.3 points.
- STE has been more active in the news (16 items in the past 4 weeks vs 10 for MYO).
- STE has more recent analyst coverage (17 ratings vs 3 for MYO).
- Company
- Myomo Inc.
- STERIS plc (Ireland)
- Price
- $1.47+5.78%
- $236.43-0.47%
- Market cap
- $58.6M
- $23.05B
- 1M return
- +40.87%
- +8.14%
- 1Y return
- +31.39%
- -4.93%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2017
- News (4w)
- 10
- 16
- Recent ratings
- 3
- 17
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
STERIS plc (Ireland)
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. This segment offers its products and services to acute care hospitals and other healthcare settings. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The company is based in Dublin, Ireland.
Latest MYO
- Amendment: Chief Medical Officer Kovelman Harry sold $30,329 worth of shares (17,500 units at $1.73), decreasing direct ownership by 14% to 105,733 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry sold $29,896 worth of shares (17,250 units at $1.73), decreasing direct ownership by 14% to 105,983 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 22,457 shares and was granted 55,149 shares, increasing direct ownership by 36% to 123,233 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah was granted 58,409 shares and covered exercise/tax liability with 21,559 shares, increasing direct ownership by 39% to 130,738 units (SEC Form 4)
- Chief Executive Officer Gudonis Paul R was granted 146,909 shares, increasing direct ownership by 11% to 1,434,679 units (SEC Form 4)
- Chief Financial Officer Henry David A was granted 68,644 shares and covered exercise/tax liability with 25,310 shares, increasing direct ownership by 10% to 470,163 units (SEC Form 4)
- SEC Form S-8 filed by Myomo Inc.
- SEC Form 10-Q filed by Myomo Inc.
- Myomo Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Myomo Reports Second Quarter 2026 Financial and Operating Results
Latest STE
- SEC Form 144 filed by STERIS plc (Ireland)
- SEC Form 4 filed by Director Shapiro Louis
- Director Sohi Mohsen exercised 4,058 units of Ordinary Shares at a strike of $86.23 and sold $956,795 worth of Ordinary Shares (4,058 units at $235.78) (SEC Form 4)
- SEC Form 4 filed by Director Shah Nirav R
- SEC Form 4 filed by Director Martin Paul Edward
- SEC Form 4 filed by Director Boulud Pierre
- SEC Form 4 filed by Director Feldmann Cynthia L
- SEC Form 4 filed by Director Holland Christopher S
- SEC Form 4 filed by Director Alegria Esther M.
- SEC Form 144 filed by STERIS plc (Ireland)